Status of HER1 and HER2 in peritoneal, ovarian and colorectal endometriosis and ovarian endometrioid adenocarcinoma

other OA: closed public-domain-us
Full text JSON View on PubMed View at publisher
AI-generated summary by claude@2026-06, 2026-06-07

This study investigated HER1 and HER2 expression via IHC and HER2 gene status via FISH in various endometriosis types and ovarian endometrioid adenocarcinoma, finding no significant role for HER1 and HER2 in endometriosis physiopathology.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

AI-generated deep summary by claude@2026-06, 2026-06-07 · read from full text

This study investigated the expression and gene status of HER1 (EGFR) and HER2 in ovarian endometriosis, peritoneal endometriosis, colorectal endometriosis, and ovarian endometrioid adenocarcinoma using immunohistochemistry, with HER2 gene status assessed by fluorescent in situ hybridisation in selected colorectal endometriosis and OEC samples. All examined samples were negative for HER2 by IHC, and HER1 by IHC was negative in glandular cells, while weak HER1 stromal expression was observed in 15 of 20 colorectal endometriosis cases. FISH found partial 17 aneusomy in two colorectal endometriosis samples and 17 polysomy in three OEC samples, with the remaining specimens showing 17 disomy without HER2 amplification. The authors conclude that HER1 and HER2 do not appear to have a role in endometriosis pathophysiology. This paper is centrally about endometriosis — it directly tests HER1/HER2 expression and gene status across peritoneal, ovarian, and colorectal endometriosis and compares these with ovarian endometrioid adenocarcinoma.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

A role for the EGF system, in particular HER1 and 2, in growth of the endometrium has been suggested but HER1 and 2 have not been studied in all locations of endometriosis and in ovarian endometrioid adenocarcinoma (OEC) which is a rare form of malignant transformation of endometriosis. Immunohistochemistry (IHC) was used for studying HER1 and HER2 in ovarian (n = 10), peritoneal (n = 10), colorectal endometriosis (n = 20) and OEC (n = 10). Fluorescent in situ hybridisation (FISH) was used for analysing the status of HER2 gene in colorectal endometriosis and OEC. All samples were negative for HER2 in both glandular and stromal cells and in glandular cells for HER1 by IHC. In 15 out of 20 colorectal endometriosis, there was a weak expression in stromal cells. Following FISH, two colorectal samples had a partial 17 aneusomy and three OEC, a 17 polysomy. The other samples were 17 disomic without HER2 amplification; HER1 and 2 do not seem to have a role in endometriosis physiopathology.
Full text 7,263 characters · extracted from oa-doi-fallback · 3 sections · click to expand

Abstract

A role for the EGF system, in particular HER1 and 2, in growth of the endometrium has been suggested but HER1 and 2 have not been studied in all locations of endometriosis and in ovarian endometrioid adenocarcinoma (OEC) which is a rare form of malignant transformation of endometriosis. Immunohistochemistry (IHC) was used for studying HER1 and HER2 in ovarian (n = 10), peritoneal (n = 10), colorectal endometriosis (n = 20) and OEC (n = 10). Fluorescent in situ hybridisation (FISH) was used for analysing the status of HER2 gene in colorectal endometriosis and OEC. All samples were negative for HER2 in both glandular and stromal cells and in glandular cells for HER1 by IHC. In 15 out of 20 colorectal endometriosis, there was a weak expression in stromal cells. Following FISH, two colorectal samples had a partial 17 aneusomy and three OEC, a 17 polysomy. The other samples were 17 disomic without HER2 amplification; HER1 and 2 do not seem to have a role in endometriosis physiopathology. Similar content being viewed by others

References

Casalini P, Iorio MV, Galmozzi E et al (2004) Role of HER receptors family in development and differentiation. J Cell Physiol 200:343–350 Bhargava R, Gerald WL, Li AR et al (2005) EGFR gene amplification in breast cancer: correlation with epidermal growth factor receptor mRNA and protein expression and HER-2 status and absence of EGFR-activating mutations. Mod Pathol 18:1027–1033 Pérez-Soler R (2004) HER1/EGFR targeting: refining the strategy. Oncologist 9:58–67 Brumm C, Rivière A, Wilckens C et al (1990) Immunohistochemical investigation and northern blot analysis of c-erB-2 expression in normal, premalignant and malignant tissues of the corpus and cervix uteri. Virchows Arch A Pathol Anat Histopathol 417:477–484 Press MF, Cordon-Cardo C, Slamon DJ (1990) Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues. Oncogene 5:953–962 Wang DP, Fujii S, Konishi I et al (1992) Expression of c-erbB-2 protein and epidermal growth factor receptor in normal tissues of the female genital tract and in the placenta. Virchows Arch A Pathol Anat Histopathol 420:385–393 Ejskjaer K, Sørensen BS, Poulsen SS et al (2005) Expression of the epidermal growth factor system in human endometrium during the menstrual cycle. Mol Hum Reprod 11:543–551 Niikura H, Sasano H, Kaga K et al (1996) Expression of epidermal growth factor family proteins and epidermal growth factor receptor in human endometrium. Hum Pathol 27:282–289 Ejskjaer K, Sørensen BS, Poulsen SS et al (2007) Expression of the epidermal growth factor system in endometrioid endometrial cancer. Gynecol Oncol 104:158–167 Stovall DW, Bowser LM, Archer DF et al (1997) Endometriosis-associated pelvic pain: evidence for an association between the stage of disease and a history of chronic pelvic pain. Fertil Steril 68:13–18 Vercellini P, Trespidi L, De Giorgi O et al (1996) Endometriosis and pelvic pain: relation to disease stage and localization. Fertil Steril 65:299–304 Jenkins S, Olive DL, Haney AF (1986) Endometriosis: pathogenetic implications of the anatomic distribution. Obstet Gynecol 67:335–338 Dubernard G, Piketty M, Rouzier R et al (2006) Quality of life after laparoscopic colorectal resection for endometriosis. Hum Reprod 21:1243–1247 Vigano P, Somigliana E, Chiodo I et al (2006) Molecular mechanisms and biological plausibility underlying the malignant transformation of endometriosis: a critical analysis. Human Reprod Update 12:77–89 Hsieh YY, Chang CC, Tsai FJ et al (2005) T homozygote, allele of epidermal growth factor receptor 2073 gene polymorphism are associated with higher susceptibility to endometriosis and leiomyomas. Fertil Steril 83:796–799 Melega C, Balducci M, Bulletti C et al (1991) Tissue factors influencing growth and maintenance of endometriosis. Ann N Y Acad Sci 622:256–265 Nasu K, Hayata T, Takai N et al (1995) Immunohistochemical study of c-erb B-2 protein expression in endometriosis. Hum Reprod 10:935–937 Schneider J, Jimenez E, Rodriguez F et al (1998) c-myc, c-erb-B2, nm23 and p53 expression in human endometriosis. Oncol Rep 5:49–52 Marwah N, Bansal C, Gupta S et al (2007) Immunohistochemical study of the expression of HER-2/neu oncogene in ovarian lesions. Indian J Pathol Microbiol 50:489–492 Berek JS, Schultes BC, Nicodemus CF (2003) Biologic and immunologic therapies for ovarian cancer. J Clin Oncol 21:168–174 Malamou-Mitsi V, Crikoni O, Timotheadou E (2007) Prognostic significance of HER-2, p53 and Bcl-2 in patients with epithelial ovarian cancer. Anticancer Res 27:1157–1165 Sasaki N, Kudoh K, Kita T et al (2007) Effect of HER-2/neu overexpression on chemoresistance and prognosis in ovarian carcinoma. J Obstet Gynaecol Res 33:17–23 Tubbs RR, Pettay JD, Roche PC et al (2001) Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: apparent immunohistochemical false-positives do not get the message. J Clin Oncol 19:2714–2721 Gong Y, Yan K, Lin F et al (2007) Determination of oestrogen-receptor status and ERBB2 status of breast carcinoma: a gene-expression profiling study. Lancet Oncol 8:203–211 Inagaki M, Yoshida S, Kennedy S et al (2007) Association study between epidermal growth factor receptor and epidermal growth factor polymorphisms and endometriosis in a Japanese population. Gynecol Endocrinol 24:1–5 Tuefferd M, Couturier J, Penault-Llorca F et al (2007) HER2 status in ovarian carcinomas: a multicenter GINECO study of 320 patients. PLoS ONE 2:1138 Noack F, Schmidt H, Buchweitz O (2004) Genomic imbalance and onco-protein expression of ovarian endometrioid adenocarcinoma arisen in an endometriotic cyst. Anticancer Res 24:151–154 Bunn PA Jr, Dziadziuszko R, Varella-Garcia M et al (2006) Biological markers for non-small cell lung cancer patient selection for epidermal growth factor receptor tyrosine kinase inhibitor therapy. Clin Cancer Res 12:3652–3656 Li AR, Chitale D, Riely GJ et al (1995) Immunohistochemical study of c-erb B-2 protein expression in endometriosis. Hum Reprod 10:935–937 Ladanyi M (2008) EGFR mutations in lung adenocarcinomas: clinical testing experience and relationship to EGFR gene copy number and immunohistochemical expression. J Mol Diagn 10:242–248 Ichihara S, Toyooka S, Fujiwara Y et al (2007) The impact of epidermal growth factor receptor gene status on gefitinib-treated Japanese patients with non-small-cell lung cancer. Int J Cancer 120:1239–1247 Kim MA, Lee HS, Lee HE et al (2008) EGFR in gastric carcinomas: prognostic significance of protein overexpression and high gene copy number. Histopathology 52:738–746

Acknowledgements

The authors want to thank P. Duvillard and F. Drusch for their efficient help in this study Conflicts of interest statement We declare that we have no conflicts of interest. Author information Authors and Affiliations Corresponding author Rights and permissions About this article Cite this article Uzan, C., Darai, E., Valent, A. et al. Status of HER1 and HER2 in peritoneal, ovarian and colorectal endometriosis and ovarian endometrioid adenocarcinoma. Virchows Arch 454, 525–529 (2009). https://doi.org/10.1007/s00428-009-0755-5 Received: Revised: Accepted: Published: Issue date: DOI: https://doi.org/10.1007/s00428-009-0755-5

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

Ask this paper AI returns verbatim quotes from the full text · source: oa-doi-fallback

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Condition tags

endometriosis

MeSH descriptors

Carcinoma, Endometrioid Endometriosis Erb-b2 Receptor Tyrosine Kinases ErbB Receptors Intestinal Diseases Ovarian Neoplasms Peritoneal Diseases Aneuploidy Biomarkers, Tumor Biomarkers, Tumor Carcinoma, Endometrioid Carcinoma, Endometrioid Cell Transformation, Neoplastic Colonic Diseases Colonic Diseases Colonic Diseases Endometriosis Endometriosis Erb-b2 Receptor Tyrosine Kinases Erb-b2 Receptor Tyrosine Kinases

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

Source provenance

europepmc
last seen: 2026-06-23T06:15:44.889181+00:00
pubmed
last seen: 2026-05-13T22:14:11.755070+00:00
unpaywall
last seen: 2026-06-02T02:00:03.124865+00:00
License: public-domain-us · commercial use OK · attribution required
Courtesy of the U.S. National Library of Medicine